Cargando…

Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line

We isolated a paclitaxel‐resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700‐fold resistance to paclitaxel and cross‐resistance to vinca alkaloids and top...

Descripción completa

Detalles Bibliográficos
Autores principales: Enokida, Hideki, Gotanda, Takenari, Oku, Shoichi, Imazono, Yoshiharu, Kubo, Hiroyuki, Hanada, Toshikatsu, Suzuki, Shigenori, Inomata, Kouhei, Kishiye, Takao, Tahara, Yoshiyuki, Nishiyama, Kenryu, Nakagawa, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927134/
https://www.ncbi.nlm.nih.gov/pubmed/12359058
http://dx.doi.org/10.1111/j.1349-7006.2002.tb02481.x
_version_ 1783319032957501440
author Enokida, Hideki
Gotanda, Takenari
Oku, Shoichi
Imazono, Yoshiharu
Kubo, Hiroyuki
Hanada, Toshikatsu
Suzuki, Shigenori
Inomata, Kouhei
Kishiye, Takao
Tahara, Yoshiyuki
Nishiyama, Kenryu
Nakagawa, Masayuki
author_facet Enokida, Hideki
Gotanda, Takenari
Oku, Shoichi
Imazono, Yoshiharu
Kubo, Hiroyuki
Hanada, Toshikatsu
Suzuki, Shigenori
Inomata, Kouhei
Kishiye, Takao
Tahara, Yoshiyuki
Nishiyama, Kenryu
Nakagawa, Masayuki
author_sort Enokida, Hideki
collection PubMed
description We isolated a paclitaxel‐resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700‐fold resistance to paclitaxel and cross‐resistance to vinca alkaloids and topoisomerase II inhibitors. Tubulin polymerization assay showed no significant difference in the ratio of polymerized α‐ and β‐tubulin between KK47/WT and KK47/TX30 cells. Western blot analysis demonstrated overexpression of P‐glycoprotein (P‐gp) and lung resistance‐related protein (LRP) in KK47/TX30 cells. Drug accumulation and efflux studies showed that the decreased paclitaxel accumulation in KK47/TX30 cells was due to enhanced paclitaxel efflux. Cell survival assay revealed that verapamil and cepharanthine, conventional P‐gp modulators, could completely overcome paclitaxel resistance. To investigate whether new synthetic isoprenoids could overcome paclitaxel resistance, we synthesized 31 isoprenoids based on the structure of N‐solanesyl‐N, N′‐bis(3,4‐dimethoxybenzyl)ethylenediamine (SDB), which could reverse multidrug resistance (MDR), as shown previously. Among those examined, trans‐N, N′‐bis(3,4‐dimethoxybenzyl)‐.N‐solanesyl‐l,2‐diaminocyclohexane (N‐5228) could completely reverse paclitaxel resistance in KK47/TX30 cells. N‐5228 inhibited photoaffinity labeling of P‐gp by [(3)H]azidopine, suggesting that N‐5228 could bind to P‐gp directly and could be a substrate of P‐gp. Next, we investigated structural features of these 31 isoprenoids in order to determine the structural requirements for the reversal of P‐gp‐mediated paclitaxel resistance, suggesting that the following structural features are important for overcoming paclitaxel resistance: (1) a basic structure of 8 to 10 isoprene units, (2) a cyclohexane ring or benzene ring within the framework, (3) two cationic sites in close proximity to each other, and (4) a benzyl group with 3, 4‐dimethoxy functionalities, which have moderate electron‐donating ability. These findings may provide valuable information for the development of P‐gp‐mediated MDR‐reversing agents.
format Online
Article
Text
id pubmed-5927134
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59271342018-05-11 Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line Enokida, Hideki Gotanda, Takenari Oku, Shoichi Imazono, Yoshiharu Kubo, Hiroyuki Hanada, Toshikatsu Suzuki, Shigenori Inomata, Kouhei Kishiye, Takao Tahara, Yoshiyuki Nishiyama, Kenryu Nakagawa, Masayuki Jpn J Cancer Res Article We isolated a paclitaxel‐resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700‐fold resistance to paclitaxel and cross‐resistance to vinca alkaloids and topoisomerase II inhibitors. Tubulin polymerization assay showed no significant difference in the ratio of polymerized α‐ and β‐tubulin between KK47/WT and KK47/TX30 cells. Western blot analysis demonstrated overexpression of P‐glycoprotein (P‐gp) and lung resistance‐related protein (LRP) in KK47/TX30 cells. Drug accumulation and efflux studies showed that the decreased paclitaxel accumulation in KK47/TX30 cells was due to enhanced paclitaxel efflux. Cell survival assay revealed that verapamil and cepharanthine, conventional P‐gp modulators, could completely overcome paclitaxel resistance. To investigate whether new synthetic isoprenoids could overcome paclitaxel resistance, we synthesized 31 isoprenoids based on the structure of N‐solanesyl‐N, N′‐bis(3,4‐dimethoxybenzyl)ethylenediamine (SDB), which could reverse multidrug resistance (MDR), as shown previously. Among those examined, trans‐N, N′‐bis(3,4‐dimethoxybenzyl)‐.N‐solanesyl‐l,2‐diaminocyclohexane (N‐5228) could completely reverse paclitaxel resistance in KK47/TX30 cells. N‐5228 inhibited photoaffinity labeling of P‐gp by [(3)H]azidopine, suggesting that N‐5228 could bind to P‐gp directly and could be a substrate of P‐gp. Next, we investigated structural features of these 31 isoprenoids in order to determine the structural requirements for the reversal of P‐gp‐mediated paclitaxel resistance, suggesting that the following structural features are important for overcoming paclitaxel resistance: (1) a basic structure of 8 to 10 isoprene units, (2) a cyclohexane ring or benzene ring within the framework, (3) two cationic sites in close proximity to each other, and (4) a benzyl group with 3, 4‐dimethoxy functionalities, which have moderate electron‐donating ability. These findings may provide valuable information for the development of P‐gp‐mediated MDR‐reversing agents. Blackwell Publishing Ltd 2002-09 /pmc/articles/PMC5927134/ /pubmed/12359058 http://dx.doi.org/10.1111/j.1349-7006.2002.tb02481.x Text en
spellingShingle Article
Enokida, Hideki
Gotanda, Takenari
Oku, Shoichi
Imazono, Yoshiharu
Kubo, Hiroyuki
Hanada, Toshikatsu
Suzuki, Shigenori
Inomata, Kouhei
Kishiye, Takao
Tahara, Yoshiyuki
Nishiyama, Kenryu
Nakagawa, Masayuki
Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
title Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
title_full Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
title_fullStr Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
title_full_unstemmed Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
title_short Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
title_sort reversal of p‐glycoprotein‐mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927134/
https://www.ncbi.nlm.nih.gov/pubmed/12359058
http://dx.doi.org/10.1111/j.1349-7006.2002.tb02481.x
work_keys_str_mv AT enokidahideki reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT gotandatakenari reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT okushoichi reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT imazonoyoshiharu reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT kubohiroyuki reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT hanadatoshikatsu reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT suzukishigenori reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT inomatakouhei reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT kishiyetakao reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT taharayoshiyuki reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT nishiyamakenryu reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline
AT nakagawamasayuki reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline